Skip to main content
. 2020 Oct 29;15(10):e0240403. doi: 10.1371/journal.pone.0240403

Fig 3. Rintatolimod-treated patients by ETT response (≥25% vs. <25%): Comparison of change from baseline in vertical rise at Week 40 for the ITT population vs. each subset.

Fig 3